Drug Profile
Research programme: cancer therapeutics - Janssen Pharmaceutica
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Belgium
- 20 Apr 2011 Early research in Cancer in Belgium (unspecified route)